Related Experiment Video
Updated: Sep 28, 2025
Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
Published on: July 14, 2023
Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events
Michie Katsuta1, Takahiro Kimura2, Kojiro Tashiro2
1Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Background/Aim:
Therapeutic strategies for prostate cancer are currently undergoing a paradigm shift due to the advent of next-generation androgen receptor inhibitors. Among these inhibitors, apalutamide is regarded as a key drug because of its effectiveness. However, risk factors for and the timing of the onset of apalutamide-related cutaneous adverse events remain unclear. Therefore, the present study investigated key risk factors for and timing of the onset of apalutamide-related cutaneous adverse events.
Patients And Methods:
Sixty-two Japanese patients with non-metastatic castration-resistant prostate cancer treated with 240 mg/day of apalutamide were enrolled in the present study.
Results:
Twenty-four patients (38.7%) developed cutaneous adverse events. Multivariable logistic regression analysis of age, height, and body weight identified body weight as a significant predictive factor for the incidence of cutaneous adverse events (p=0.019). When the mean body weight of patients (63.80 kg) was set as the cut-off value, the Kaplan-Meier analysis revealed that the risk of cutaneous adverse events was significantly increased in those with a body weight <63.8 kg (p=0.003, the log-rank test). The analysis also showed that cutaneous adverse events developed within the first 6 months regardless of body weight.
Conclusion:
A lower body weight is a significant risk factor for apalutamide-related cutaneous adverse events and their onset is within 6 months of initiation of therapy.
Insights
Lower body weight is a key risk factor for developing skin side effects from apalutamide, a prostate cancer drug. These adverse events typically occur within six months of starting treatment.
Area of Science:
- Oncology
- Pharmacology
- Dermatology
Background:
- Prostate cancer treatment is evolving with new androgen receptor inhibitors.
- Apalutamide is an effective next-generation inhibitor.
- Understanding apalutamide-related skin adverse events is crucial.
Purpose of the Study:
- To identify risk factors for apalutamide-induced cutaneous adverse events.
- To determine the onset timing of these adverse events.
Main Methods:
- Study included 62 Japanese patients with non-metastatic castration-resistant prostate cancer.
- Patients received 240 mg/day of apalutamide.
- Statistical analyses included multivariable logistic regression and Kaplan-Meier analysis.
Main Results:
- 38.7% of patients experienced cutaneous adverse events.
- Lower body weight (<63.8 kg) was a significant predictor of these events (p=0.019).
- Adverse events occurred within 6 months of treatment initiation.
Conclusions:
- Lower body weight is a significant risk factor for apalutamide-related skin issues.
- Onset of these adverse events is typically within the first six months of therapy.
Related Concept Videos
01:21Drug Distribution: Tissue Binding
For...
01:25Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation